BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 02/01/2026

FDA Withdraws MYSOLINE Suspension from Sale Due to Safety or Effectiveness Concerns

The FDA has determined that MYSOLINE suspension, 250 mg/5 mL, was withdrawn from sale due to safety or effectiveness concerns, and will not accept new applications for this product.

Source: Federal Register — Food and Drug AdministrationOpen original release →